Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2000
11/21/2000US6150362 Administering 1,3,5-substituted triazine compounds to the patient suffering from angiogenic diseases
11/21/2000US6150359 Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
11/21/2000US6150352 Antagonists of gonadotropin releasing hormone
11/21/2000US6150343 10-hydroxy-7-substituted silylcamptothecin derivative is used as anticarcinogenic and antitumor agent
11/21/2000US6150325 Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical compositions
11/21/2000US6150116 Transcription factor DP-1 antibody
11/21/2000US6150101 Methods of identifying a composition that alters connective tissue growth factor expression
11/21/2000US6149947 Compositions of oak bark extract related synthetic compositions and method of using same
11/21/2000US6149671 Laser/sensitizer assisted immunotherapy
11/21/2000CA2203694C Cancer inhibitory peptides
11/21/2000CA2020477C Sustained release formulations of water soluble peptides
11/21/2000CA1341142C Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
11/18/2000CA2684454A1 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
11/16/2000WO2000068387A2 Nucleic acids and proteins with interferon-beta activity
11/16/2000WO2000068385A2 Novel nucleic acids and proteins with growth hormone activity
11/16/2000WO2000068384A2 NOVEL NUCLEIC ACIDS AND PROTEINS WITH p53 ACTIVITY AND ALTERED TETRAMERIZATION DOMAINS
11/16/2000WO2000068380A2 Extracellular matrix and adhesion-associated proteins
11/16/2000WO2000068379A1 Methods for treating tumors using antiangiogenic compounds
11/16/2000WO2000068263A2 Stereoselective antifibrillogenic peptides and peptidomimetics thereof
11/16/2000WO2000068254A1 Spray drying of thrombin inhibitors
11/16/2000WO2000068247A2 Serine proteases
11/16/2000WO2000068246A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000WO2000068223A1 Ureas and their use as cell adhesion modulators
11/16/2000WO2000068215A1 Diphenyl-1,2,3-thiadiazol-3-oxides, compositions and methods of use
11/16/2000WO2000068213A1 Substituted bicyclic compounds
11/16/2000WO2000068206A1 Heterocyclically substituted benzimidazoles, the production and application thereof
11/16/2000WO2000068201A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068200A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068199A1 Quinoline derivatives as inhibitors of mek enzymes
11/16/2000WO2000068198A2 Heterosubstituted pyridine derivatives as pde 4 inhibitors
11/16/2000WO2000068195A2 Substituted pyrrolidines as cell adhesion inhibitors
11/16/2000WO2000068185A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000WO2000067801A2 Prodrugs of chemotherapeutic agents with oxaalkanoic acids
11/16/2000WO2000067800A2 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
11/16/2000WO2000067796A1 Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
11/16/2000WO2000067795A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
11/16/2000WO2000067793A1 Death domain containing receptor 4
11/16/2000WO2000067792A1 Monoclonal antibody directed against cells of human renal cell carcinoma
11/16/2000WO2000067788A2 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000WO2000067776A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
11/16/2000WO2000067769A1 Enhanced survival of cancer patients treated with erythropoietin and antitumor agents
11/16/2000WO2000067762A2 Selenium-containing pro-drugs for cancer therapy
11/16/2000WO2000067761A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000WO2000067760A1 Liposome preparation of fat-soluble antitumor drug
11/16/2000WO2000067746A1 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
11/16/2000WO2000067734A2 Use of phthalazine derivatives
11/16/2000WO2000067698A2 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation
11/16/2000WO2000067697A2 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000WO2000048996A3 β-ALANINE DERIVATIVES
11/16/2000WO2000044389A3 Method for preparing membrane vesicles
11/16/2000WO2000043501A3 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
11/16/2000WO2000042179A3 Complex-forming proteins
11/16/2000WO2000042168A3 Bifidobacterium in the treatment of inflammatory disease
11/16/2000WO2000041717A3 Chorionic gonadotropin dna vaccines and methods
11/16/2000WO2000041669A3 Benzimidazole vascular damaging agents
11/16/2000WO2000041469A3 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS
11/16/2000WO2000038665A3 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
11/16/2000WO2000037639A3 Lymphocytic membrane proteins
11/16/2000WO2000037613A3 Human akt-3
11/16/2000WO2000037025A3 Antibodies to truncated vegf-d and uses thereof
11/16/2000WO2000036118A3 HUMAN CYCLIN-DEPENDENT KINASE (hPNQALRE)
11/16/2000WO2000033874B1 Boron neutron capture therapy using pre-targeting methods
11/16/2000WO2000032186A3 Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
11/16/2000WO2000029015A3 INFLUENCING OF ANGIGENESIS USING CD66a
11/16/2000WO2000029012A3 Methods of alleviating cancer symptoms
11/16/2000WO2000026370A3 Adenine nucleotide translocator (ant) fusion proteins and uses thereof
11/16/2000WO2000026247A3 Ikaros isoforms and mutants
11/16/2000WO2000023466A3 Human rna binding proteins
11/16/2000WO2000023464A3 Zinc finger binding domains for gnn
11/16/2000WO2000020448A3 Nlk1 -interacting proteins
11/16/2000WO2000020358A3 NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION
11/16/2000WO2000009549A3 Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use
11/16/2000WO2000007543A8 Conjugates targeted to the interleukin-2 receptors
11/16/2000WO2000005375A9 Gbs toxin receptor
11/16/2000WO2000001713A3 Diacylglycerol acyl transferase proteins
11/16/2000WO2000000157A3 Use of tempo and tempo derivatives for inducing cell death
11/16/2000DE19922407A1 Preparing medicament for treating viral infections, liver diseases or cancer, comprising recombinant parapoxvirus targeted towards specific organs, cells or tissues
11/16/2000DE19921567A1 Verwendung von Phthalazine-Derivaten Use of derivatives phthalazines
11/16/2000DE19921346A1 Sprühtrocknung von Thrombininhibitoren Spray drying of thrombin inhibitors
11/16/2000DE19921101A1 Neue spirocyclische Verbindungen, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung hyperproliferativer Erkrankungen New spirocyclic compounds, processes for their preparation and their use for the treatment of hyperproliferative diseases
11/16/2000DE19920247A1 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung Medicaments with an amount of compounds having a nitrogen-oxygen heterocycle as active ingredient and their use
11/16/2000DE19919225A1 Tumorassoziiertes Antigen Tumor-associated antigen
11/16/2000DE19919149A1 Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere Of interferon alpha-2 derived peptide homodimers and peptide heterodimers
11/16/2000DE19919148A1 Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere Interleukin 12 derived peptide homodimers and peptide heterodimers
11/16/2000CA2388092A1 Stereoselective antifibrillogenic peptides and peptidomimetics thereof
11/16/2000CA2374237A1 Compositions and methods for identifying antigens which elicit an immune response
11/16/2000CA2373851A1 Nucleic acid-antibody conjugate for delivering a foreign nucleic acid in cells
11/16/2000CA2373759A1 Serine proteases
11/16/2000CA2373672A1 Method for controlling the fidelity and execution of reverse transcriptase by incorporating and polymerising nucleotide analogues acceptable as substrates without blocking its elongation
11/16/2000CA2373631A1 Monoclonal antibody directed against cells of human renal cell carcinoma
11/16/2000CA2373618A1 Immunotherapy of b-cell malignancies using anti-cd22 antibodies
11/16/2000CA2373443A1 Steroid compounds with a c17-alkyl side chain and an aromatic a-ring for use in therapy
11/16/2000CA2373256A1 Use of soluble costimulatory molecules to enhance immune responses
11/16/2000CA2373182A1 A structure-based approach to design inhibitors of protein-processivity factor interactions
11/16/2000CA2373068A1 Spray drying of thrombin inhibitors
11/16/2000CA2373063A1 Death domain containing receptor 4
11/16/2000CA2372881A1 Novel nucleic acids and proteins with p53 activity and altered tetramerization domains
11/16/2000CA2372871A1 Novel nucleic acids and proteins with growth hormone activity
11/16/2000CA2372815A1 Extracellular matrix and adhesion-associated proteins
11/16/2000CA2372782A1 Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
1 ... 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 ... 2211